MedTrace Logo

Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical

NCT06643494 · Status: SUSPENDED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-03-11

No results posted yet for this study

Summary

Does nutraceutical N-111 lower the number of side effects occurring during ADT + External Beam Radiation (EBR) prostate cancer treatment?

Conditions

Interventions

DIETARY_SUPPLEMENT

N-111

A combination of Acetogenins

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Optimal Health Research

    lead OTHER

Principal Investigators

  • Alan Jeppsen, MD · Optimal Health Research

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-15
Primary Completion
2026-09-15
Completion
2026-12-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06643494 on ClinicalTrials.gov